186 related articles for article (PubMed ID: 33801444)
41. Characterization of the treatment-naive immune microenvironment in melanoma with
Wang M; Zadeh S; Pizzolla A; Thia K; Gyorki DE; McArthur GA; Scolyer RA; Long G; Wilmott JS; Andrews MC; Au-Yeung G; Weppler A; Sandhu S; Trapani JA; Davis MJ; Neeson PJ
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383113
[TBL] [Abstract][Full Text] [Related]
42. Downregulation of PDCD4 by miR-21 suppresses tumor transformation and proliferation in a nude mouse renal cancer model.
Yuan H; Xin S; Huang Y; Bao Y; Jiang H; Zhou L; Ren X; Li L; Wang Q; Zhang J
Oncol Lett; 2017 Sep; 14(3):3371-3378. PubMed ID: 28927090
[TBL] [Abstract][Full Text] [Related]
43. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
44. Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression.
García-Mulero S; Alonso MH; Del Carpio LP; Sanz-Pamplona R; Piulats JM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800878
[TBL] [Abstract][Full Text] [Related]
45. Programmed cell death ligand-1 expression in tumor and immune cells is associated with better patient outcome and decreased tumor-infiltrating lymphocytes in uveal melanoma.
Zoroquiain P; Esposito E; Logan P; Aldrees S; Dias AB; Mansure JJ; Santapau D; Garcia C; Saornil MA; Belfort Neto R; Burnier MN
Mod Pathol; 2018 Aug; 31(8):1201-1210. PubMed ID: 29581543
[TBL] [Abstract][Full Text] [Related]
46. Hypermethylation and Expression Silencing of PDCD4 Gene in Hepatocellular Carcinoma: A Consort Study.
Ding X; Cheng X; Gong M; Chen X; Yin F; Lai K
Medicine (Baltimore); 2016 Feb; 95(6):e2729. PubMed ID: 26871813
[TBL] [Abstract][Full Text] [Related]
47. Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.
Kamamoto D; Ohara K; Kitamura Y; Yoshida K; Kawakami Y; Sasaki H
J Neurooncol; 2018 Sep; 139(2):251-259. PubMed ID: 29675794
[TBL] [Abstract][Full Text] [Related]
48. Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma.
Liu D; Yang X; Wu X
Front Immunol; 2021; 12():663495. PubMed ID: 34025664
[TBL] [Abstract][Full Text] [Related]
49. Tumour suppressive function and modulation of programmed cell death 4 (PDCD4) in ovarian cancer.
Wei N; Liu SS; Chan KK; Ngan HY
PLoS One; 2012; 7(1):e30311. PubMed ID: 22272332
[TBL] [Abstract][Full Text] [Related]
50. Prognostic significance of PDCD4 expression and association with microRNA-21 in each Dukes' stage of colorectal cancer patients.
Horiuchi A; Iinuma H; Akahane T; Shimada R; Watanabe T
Oncol Rep; 2012 May; 27(5):1384-92. PubMed ID: 22267128
[TBL] [Abstract][Full Text] [Related]
51. Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo.
Gaur AB; Holbeck SL; Colburn NH; Israel MA
Neuro Oncol; 2011 Jun; 13(6):580-90. PubMed ID: 21636706
[TBL] [Abstract][Full Text] [Related]
52. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
[TBL] [Abstract][Full Text] [Related]
53. Tumor Suppressor p53 Down-Regulates Programmed Cell Death Protein 4 (PDCD4) Expression.
Yang WH; George AP; Wang CM; Yang RH; Duncan AM; Patel D; Neil ZD; Yang WH
Curr Oncol; 2023 Jan; 30(2):1614-1625. PubMed ID: 36826085
[TBL] [Abstract][Full Text] [Related]
54. Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma.
Zhen Y; Liu Z; Yang H; Yu X; Wu Q; Hua S; Long X; Jiang Q; Song Y; Cheng C; Wang H; Zhao M; Fu Q; Lyu X; Chen Y; Fan Y; Liu Y; Li X; Fang W
Cell Death Dis; 2013 Oct; 4(10):e872. PubMed ID: 24157866
[TBL] [Abstract][Full Text] [Related]
55. Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies.
Wagner NB; Weide B; Gries M; Reith M; Tarnanidis K; Schuermans V; Kemper C; Kehrel C; Funder A; Lichtenberger R; Sucker A; Herpel E; Holland-Letz T; Schadendorf D; Garbe C; Umansky V; Utikal J; Gebhardt C
J Immunother Cancer; 2019 Dec; 7(1):343. PubMed ID: 31806053
[TBL] [Abstract][Full Text] [Related]
56. Programmed cell death 4 inhibits breast cancer cell invasion by increasing tissue inhibitor of metalloproteinases-2 expression.
Nieves-Alicea R; Colburn NH; Simeone AM; Tari AM
Breast Cancer Res Treat; 2009 Mar; 114(2):203-9. PubMed ID: 18386173
[TBL] [Abstract][Full Text] [Related]
57. Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions.
Cappellesso R; Tinazzi A; Giurici T; Simonato F; Guzzardo V; Ventura L; Crescenzi M; Chiarelli S; Fassina A
Cancer Cytopathol; 2014 Sep; 122(9):685-93. PubMed ID: 24888238
[TBL] [Abstract][Full Text] [Related]
58. ZEB1 transcription factor promotes immune escape in melanoma.
Plaschka M; Benboubker V; Grimont M; Berthet J; Tonon L; Lopez J; Le-Bouar M; Balme B; Tondeur G; de la Fouchardière A; Larue L; Puisieux A; Grinberg-Bleyer Y; Bendriss-Vermare N; Dubois B; Caux C; Dalle S; Caramel J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288462
[TBL] [Abstract][Full Text] [Related]
59. Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis.
Chusorn P; Namwat N; Loilome W; Techasen A; Pairojkul C; Khuntikeo N; Dechakhamphu A; Talabnin C; Chan-On W; Ong CK; Teh BT; Yongvanit P
Tumour Biol; 2013 Jun; 34(3):1579-88. PubMed ID: 23417858
[TBL] [Abstract][Full Text] [Related]
60. Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.
Fröhlich A; Sirokay J; Fietz S; Vogt TJ; Dietrich J; Zarbl R; Florin M; Kuster P; Saavedra G; Valladolid SR; Hoffmann F; Flatz L; Ring SS; Golletz C; Pietsch T; Strieth S; Brossart P; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Sep; 59():102962. PubMed ID: 32861198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
